<DOC>
	<DOC>NCT00520676</DOC>
	<brief_summary>The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patient with locally advanced or metastatic (Stage IIIB/IV) NCSLC with no prior chemotherapy for advanced disease or molecular target treatment Easter Cooperative Oncology Group (ECOG) performance status 0 to 2 Estimated life expectancy of at least 8 weeks Known or suspected brain metastases Concurrent administration of any other tumor therapy Serious concomitant disorders Pregnancy or breast feeding Inability or unwillingness to take folic acid or vitamin B12 supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>